Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03667716 · ClinicalTrials.gov registry record · Phase 1
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
A Phase 1 study, sponsored by Compugen.
- Completed
- Registry status
- Phase 1
- Development phase
- 121
- Enrollment target
NCT03667716 is a Phase 1 study that has completed, run by Compugen. The registered enrollment target is 121 participants.
The verdict
NCT03667716, a Phase 1 study, has completed, sponsored by Compugen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
Interventions
- DRUG COM701
- DRUG COM701 with Opdivo (Nivolumab).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2018-09-06 |
| Est. Completion | 2024-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03667716
The ClinicalTrials.gov registry entry for NCT03667716 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Compugen, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which COM701 is the first listed.
NCT03667716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03667716 about?
NCT03667716 is a clinical study titled "COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.". This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
What is the current status of trial NCT03667716?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 121 participants. The study started on 2018-09-06. Estimated completion is 2024-01-30.
What interventions are being tested in trial NCT03667716?
The interventions under investigation include: COM701 (DRUG), COM701 with Opdivo (Nivolumab). (DRUG).
Who is sponsoring clinical trial NCT03667716?
This trial is sponsored by Compugen, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.